Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due to menopause and patient-reported sleep disturbance at 24 weeks Women considered unsuitable included those with contraindications, who are averse to taking, have stopped taking or have conditions that suggest caution in using hormone therapy Results will support health technology a...

Related Keywords

Tokyo ,Japan ,Netherlands ,Turkey ,Amsterdam ,Noord Holland ,Canada ,Rossella Nappi ,Naoki Okamura ,San Matteo Foundation ,University Of Pavia ,European Society Of Gynecology ,Elsevier ,Astellas Pharma Inc ,Head Of Biopharma Development ,Research Center ,Health Qual Life Outcomes ,Astella Fezolinetant Reduces Frequency ,Women Considered Unsuitable ,European Society ,Full Professor ,Reproductive Medicine ,Gynecological Endocrinology ,Menopause Unit ,Imatteo Foundation ,Vice President ,Biopharma Development ,Short Form ,Focus Area Approach ,Equal Life ,Clin Endocrinol ,Press Release Image ,Phase ,Tb ,Daylight ,Study ,Resented ,Sg ,023 ,Remonstrated ,Fezolinetant ,5 ,G ,Chieved ,Statistically ,Significant ,Reductions ,Frequency ,Severity ,Moderate ,Evere ,Vasomotor ,Symptoms ,Menopause ,Patient Reported ,Sleep ,Disturbance ,4 ,Eeks ,Women ,Onsidered ,Unsuitable ,Ncluded ,Contraindications ,Verse ,Baking ,Topped ,Conditions ,Uggest ,Caution ,Sing ,Ormone ,Therapy ,Results ,Support ,Health ,Technology ,Ebwire ,Press Release ,Ews Release ,